From July 2023, the primary test for cervical screening will change to a human papillomavirus (HPV) test, with the option of self-testing. The current cytology-based test has served New Zealand well for over 20 years and played a huge role in reducing cervical cancer mortality.

Brightstar in association with Shea Pita & Associates proudly present Mana Taurite I Equity in Health from 4-5 December 2023 at the Millennium Hotel in Tāmaki Makaurau (Auckland).